NCT04998812 - A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 13, 2022

Primary Completion Date

April 8, 2024

Study Completion Date

July 14, 2025

Conditions

Multiple SclerosisClinically Isolated Syndrome

Interventions

DRUG

Ocrelizumab

Post-partum dosing and treatment duration are at the discretion of the physicians, in accordance with local clinical practice and local labelling.

Trial Locations (12)

Inselspital Bern, Bern

Universitätsspital Basel, Basel

Hospital of the University of Pennsylvania, Philadelphia

MultipEL Studies - Institut für klinische Studien, Hamburg

Hosp. Clinico San Carlos, Madrid

St. Josef Hospital GmbH, Bochum

Hopital Pierre Wertheimer - Hopital Neurologique, Bron

Hôpital de la Pitié Salpétrière, Paris

University Of Colorado, Aurora

University of California San Francisco, San Francisco

Northwestern Memorial Hospital, Chicago

Universitaetsklinikum Carl Gustav Carus an der TU Dresden, Dresden